Branded Legacy, Inc. Forms Strategic Partnership with Stanford University's Dr. Eran Bendavid to Advance Addiction Solutions
Branded Legacy (OTC: BLEG) has announced a strategic partnership with Stanford University's Dr. Eran Bendavid to advance addiction treatment solutions. The collaboration integrates Stanford's AI-powered systematic review platform for rapid evidence synthesis with BLEG's drug development initiatives, particularly focusing on intranasal naloxone development.
This partnership follows BLEG's recent acquisition of Bio-Legacy Evaluative Group and collaboration with McMaster University. The company aims to leverage Dr. Bendavid's expertise in global health and policy analysis to optimize its product strategy in the naloxone market, which is projected to grow from $371 million in 2022 to $1.16 billion by 2032 at a CAGR of 11.9%.
Branded Legacy (OTC: BLEG) ha annunciato una partnership strategica con Dr. Eran Bendavid dell'Universit脿 di Stanford per potenziare le soluzioni nel trattamento delle dipendenze. La collaborazione unisce la piattaforma di revisioni sistematiche basata su IA di Stanford, per una rapida sintesi delle evidenze, alle iniziative di sviluppo farmaceutico di BLEG, con particolare attenzione allo sviluppo di naloxone per somministrazione intranasale.
Questa intesa arriva dopo l'acquisizione da parte di BLEG del Bio-Legacy Evaluative Group e la collaborazione con la McMaster University. L'azienda intende sfruttare l'esperienza del Dr. Bendavid in salute globale e analisi delle politiche per ottimizzare la strategia di prodotto nel mercato del naloxone, che si prevede passer脿 da 371 milioni di dollari nel 2022 a 1,16 miliardi entro il 2032, con un CAGR dell'11,9%.
Branded Legacy (OTC: BLEG) ha anunciado una alianza estrat茅gica con el Dr. Eran Bendavid de la Universidad de Stanford para impulsar soluciones en el tratamiento de las adicciones. La colaboraci贸n integra la plataforma de revisiones sistem谩ticas con IA de Stanford, dise帽ada para sintetizar evidencia r谩pidamente, con las iniciativas de desarrollo farmac茅utico de BLEG, centradas especialmente en el desarrollo de naloxona intranasal.
Esta asociaci贸n sigue a la reciente adquisici贸n por parte de BLEG del Bio-Legacy Evaluative Group y su colaboraci贸n con la Universidad McMaster. La compa帽铆a busca aprovechar la experiencia del Dr. Bendavid en salud global y an谩lisis de pol铆ticas para optimizar su estrategia de producto en el mercado de la naloxona, que se prev茅 crecer谩 de 371 millones de d贸lares en 2022 a 1.160 millones en 2032, con una TCCA del 11,9%.
Branded Legacy (OTC: BLEG)電� 欷戨弲 旃橂 靻旊（靺橃潉 氚滌爠鞁滍偆旮� 鞙勴暣 鞀ろ儬韻茧摐雽�頃欔祼鞚� 鞐愲瀫 氩る嫟牍勲摐 氚曥偓鞕� 鞝勲灥鞝� 韺岉姼雱堨嫮鞚� 觳搓舶頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚措矆 順戨牓鞚� 鞀ろ儬韻茧摐鞚� 鞚戈车歆�電� 旮半皹 觳搓硠鞝� 氍疙棇瓴�韱� 頂岆灚韽检潉 韱淀暅 鞁犾啀頃� 攴缄卑 膦呿暕瓿� BLEG鞚� 鞎诫 臧滊皽 頇滊彊鞚� 瓴绊暕頃橂┌, 韸鬼瀳 牍勱皶 韴棳順� 雮犽靻� 臧滊皽鞐� 欷戩爯鞚� 霊‰媹雼�.
鞚� 韺岉姼雱堨嫮鞚� BLEG臧� 斓滉芳 Bio-Legacy Evaluative Group鞚� 鞚胳垬頃橁碃 毵ル鞀ろ劙 雽�頃欔祼鞕� 順戨牓頃� 雿� 鞚挫潃 瓴冹瀰雼堧嫟. 須岇偓電� 氩る嫟牍勲摐 氚曥偓鞚� 旮�搿滊矊 氤搓贝 氚� 鞝曥眳 攵勳劃 鞝勲靹膘潉 頇滌毄頃� 2022雲� 3鞏�7,100毵� 雼煬鞐愳劀 2032雲� 11鞏�6,000毵� 雼煬搿� 靹膘灔頃� 瓴冹溂搿� 鞓堨儊霅橂姅 雮犽靻� 鞁滌灔鞐愳劀 鞝滍拡 鞝勲灥鞚� 斓滌爜頇旐晿霠り碃 頃╇媹雼�. 鞐绊弶攴� 靹膘灔毳犾潃 11.9%搿� 鞝勲霅╇媹雼�.
Branded Legacy (OTC: BLEG) a annonc茅 un partenariat strat茅gique avec le Dr Eran Bendavid de l'universit茅 de Stanford afin de faire progresser les solutions de traitement des addictions. Cette collaboration associe la plateforme d'examen syst茅matique pilot茅e par IA de Stanford, pour une synth猫se rapide des preuves, aux initiatives de d茅veloppement pharmaceutique de BLEG, en mettant l'accent sur le d茅veloppement de naloxone en administration intranasale.
Ce partenariat fait suite 脿 la r茅cente acquisition par BLEG du Bio-Legacy Evaluative Group et 脿 sa collaboration avec l'universit茅 McMaster. La soci茅t茅 entend tirer parti de l'expertise du Dr Bendavid en sant茅 mondiale et en analyse des politiques pour optimiser sa strat茅gie produit sur le march茅 de la naloxone, qui devrait passer de 371 millions de dollars en 2022 脿 1,16 milliard en 2032, avec un TCAC de 11,9 %.
Branded Legacy (OTC: BLEG) hat eine strategische Partnerschaft mit Dr. Eran Bendavid von der Stanford University bekanntgegeben, um Behandlungsl枚sungen f眉r Sucht voranzutreiben. Die Zusammenarbeit verbindet Stanfords KI-gest眉tzte Plattform f眉r systematische Reviews zur schnellen Evidenzsynthese mit BLEGs Arzneimittelentwicklungsprojekten, mit besonderem Fokus auf die Entwicklung von intranasalem Naloxon.
Die Partnerschaft folgt auf BLEGs k眉rzliche 脺bernahme der Bio-Legacy Evaluative Group und die Kooperation mit der McMaster University. Das Unternehmen will Dr. Bendavids Fachwissen in globaler Gesundheit und Politik颅analyse nutzen, um seine Produktstrategie im Naloxon-Markt, der von 371 Millionen US-Dollar im Jahr 2022 auf 1,16 Milliarden US-Dollar bis 2032 wachsen soll, bei einer j盲hrlichen Wachstumsrate (CAGR) von 11,9%, zu optimieren.
- Strategic partnership with Stanford University's Dr. Eran Bendavid enhances research capabilities
- Access to Stanford's AI-powered systematic review platform enables real-time research analysis
- Targeting growing naloxone market projected to reach $1.16B by 2032
- Recent strategic acquisitions and partnerships strengthen market position
- Operating in highly competitive and regulated addiction treatment market
- Success depends on regulatory approvals and market adoption
Pioneering Evidence-Led Innovation to Combat the Global Opioid Crisis
VANCOUVER, British Columbia, Aug. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (), a leading diversified holdings company dedicated to pioneering health and wellness solutions, today announced a strategic partnership with Dr. Eran Bendavid, Professor at Stanford University, to strengthen addiction research through advanced evidence synthesis and policy analysis. This collaboration builds on Branded Legacy's recent acquisition of Bio-Legacy Evaluative Group and its partnership with McMaster University, reinforcing its commitment to developing evidence-led, scalable solutions for the global addiction crisis.
The partnership leverages Dr. Bendavid's expertise in global health and policy with Branded Legacy's innovation in addiction-focused drug development. "The addiction landscape is intricately shaped not just by medical science, but also by how health systems respond, especially under stress," said Dr. Bendavid. "By combining rapid evidence synthesis with policy analysis, this collaboration will help ensure that innovations are both effective and implementable in real-world settings."
Central to this alliance is Stanford's AI-powered systematic review platform, which can process and distill large volumes of scientific literature in minutes, unlike traditional reviews that take months. This enables Branded Legacy to stay aligned with the latest medical evidence in near real-time. Amin Janmohamed, CEO of Branded Legacy, stated, "With Dr. Bendavid's systems-level insight and this state-of-the-art literature review engine, Branded Legacy gains a powerful advantage: we can integrate the latest research in near real-time, grounding our pipeline in the strongest evidence base available."
The collaboration enhances Branded Legacy's focus on intranasal naloxone development, informed by global health modeling and real-time evidence monitoring. With the opioid crisis, driven by fentanyl, demanding fast-acting and adaptable solutions, this partnership positions Branded Legacy to optimize its naloxone product strategy for maximum public health impact, addressing acute overdose deaths while preparing for long-term system-level adoption.
By merging health system insights, rapid evidence review, and product innovation, Branded Legacy and Dr. Bendavid's team are creating a framework that ensures BLEG's innovations are supported by cutting-edge academic expertise and dynamic intelligence, building a pathway from local product innovation to global adoption. These scientifically rigorous, policy-informed, and globally relevant interventions strengthen Branded Legacy's mission to create scalable solutions for populations affected by addiction, driving innovation toward global adoption and transformative public health impact.
These milestones鈥攖he acquisition of Bio-Legacy Evaluative Group, the McMaster University partnership, and now the Stanford collaboration鈥攑osition Branded Legacy as a leader in biotech innovation for addiction treatment. The company continues to target the naloxone market, projected to grow from
About Branded Legacy, Inc.
Branded Legacy, Inc.听(翱罢颁: BLEG) is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. Its patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment. The platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions, driving shareholder value.
Investor Relations:聽
Branded Legacy, Inc.聽聽
贰尘补颈濒:听
Phone: 877-250-9077
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including projections regarding market growth, revenue potential, and development timelines, are based on current expectations and beliefs and involve risks and uncertainties that could cause actual results to differ materially. Branded Legacy undertakes no obligation to update these statements except as required by law.
FAQ
What is the strategic partnership between Branded Legacy (BLEG) and Stanford University?
How will Stanford's AI platform benefit Branded Legacy's research?
What is the projected growth of the naloxone market that Branded Legacy is targeting?
What recent acquisitions has Branded Legacy (BLEG) completed?
How does this partnership affect Branded Legacy's product development?
